Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Res Treat. 2011 Dec;43(4):231-5. doi: 10.4143/crt.2011.43.4.231. Epub 2011 Dec 27.

Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study.

Author information

  • 1Department of Urology, Hospital 9 de Julho of São Paulo, São Paulo, Brazil.

Abstract

PURPOSE:

High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined.

MATERIALS AND METHODS:

A total of 140 high-risk prostate cancer patients who were undergoing definitive treatment and who had clinically organ-confined disease and who suffered from biochemical recurrence were administered intravenous (IV) clodronate. The patients were treated with a radical retropubic prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length of time until the first bone metastasis was recorded and analyzed.

RESULTS:

No statistical difference was found for the type of primary treatment (RP or RTx) on the time to the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was a clear advantage favoring the group that received bisphosphonate (p<0.001). The addition of bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1 to 15.4; p<0.001).

CONCLUSION:

Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk prostate cancer patients who were experiencing an increase in the prostate specific antigen level after definitive treatment.

KEYWORDS:

Androgen antagonists; Clodronic acid; Hormone antagonists; Osteoporosis; Prostatic neoplasms; Zoledronic acid

PMID:
22247708
[PubMed]
PMCID:
PMC3253865
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Publishing M2Community Icon for PubMed Central
    Loading ...
    Write to the Help Desk